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Abstract 
The determination of neopterin is a new method for monitoring diseases which are linked with the activation of the immunity. This 
study was done to verify serum neopterin concentrations as a marker of virological infection with hepatitis C virus (genotype 4) in 
Egyptian blood donors. A total of 88 blood samples were collected from VACSERA blood bank by venipuncture and serum was 
obtained by centrifugation. Serum antibodies against Human Immunodeficiency Virus (HIV-1&2), Hepatitis C Virus (HCV Ab and 
PCR), and Hepatitis B Virus surface antigen (HBsAg) were determined in all samples by routine ELISA method. Serum neopterin 
was measured by a commercially neopterin enzyme Immunoassay kit. The diagnostic accuracy of marker was assessed using 
receiver-operating characteristic (ROC) curve analysis, describing the area under the curve (AUC) and its 95% confidence interval 
(CI). The samples were classified into two groups: Group I: 44 blood sample with HCV negative. Group II: 44 normal blood sample 
positive to HCV. Results showed that 9.09% HCV positive donors while 15.90% control group donors had increased neopterin level. 
Mean serum neopterin levels were elevated in healthy group (6.419 nmol/l) comparable to the HCV positive group (5.78 nmol/l) (P ˃ 
0.05). When HCV patients were compared to healthy group, AUC for neopterin and HCV Ab were 0.526. Based on the ROC 
analysis, there were no adequate cut-off values for neopterin that would be best for differentiation of HCV from the non HCV 
patients. It is concluded that Neopterin assay isn’t a good diagnostic marker for HCV in blood donors. 
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INTRODUCTION 
Hepatitis C is a blood-borne virus where it attributed as 
non-A/non-B hepatitis. The virus attacks cells in the liver, 
multiplies (replicates) (Andrade et al., 2009). There are 
estimates of 3% of the world’s population being chronically 
infected with HCV, that is the main source of liver fibrosis, 
cirrhosis and hepatocellular carcinoma (HCC) (Mohamed 
and Attalah., 2014). The risk factors linked with HCC 
comprise age, sex, diet, alcohol, and hepatitis B virus (HBV) 
and/or hepatitis C virus (HCV) infection (Ali et al., 2015). 
Only in case of known diseases, there are specific tests 
available for detection of microorganisms. There was a 
remarkable progress in regard to safety of blood transfusion 
either by serologic or molecular biology techniques aiding 
blood donor screening, screening of the blood donors for 
elevated levels of liver enzymes in the blood for hepatitis, 
followed by Hepatitis B and then Hepatitis C   screening was 
done   (Shameem Banu et al., 2011). 
Neopterin screening of blood transfusions became 
mandatory in Austria. Increased neopterin concentrations 
are helpful for the detection of subclinical infections or silent 
systemic disorders (Eisenhut., 2013).                                                         
Neopterin serum levels above 10 nmol/L are considered 
as elevated. Therefore, the assessment of neopterin in 
blood samples is a convenient tool in order to diminish the 
risk of infections via blood transfusion. Thereby it has to be 
noted that neopterin levels are already raised in an early 
stage of an infection, even before specific antibodies are 
produced to be  able to further close the so-called "window 
period" which still prevail when antibody screening is done 
(Inci Fisenk et al., 2005; Shameem Banu et al., 2011). 
The purpose of this study was to demonstrate 
association of serum Neopterin level with HCV infection 
among Egyptian blood donors. 
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MATERIALS AND METHODS 
This study was organized using 88 blood samples 
collected from blood bank of VACSERA in 2013, all samples 
were screened for HCV antibodies and PCR, hepatitis B 
surface antigen, hepatitis B core antibodies, HIV-1 and-2 
antibodies. The two groups all of matched sex. 
Accordingly, the samples were divided into 2 groups: 
Group I: include 44 donors (male aged between 19-45 years 
and negative for HIV antibody, hepatitis B surface antigen, 
hepatitis B core antibodies, HCV by antibodies and PCR). 
Group II: include 44 donors (male aged between 21-45 
years and negative for HIV antibody, hepatitis B surface 
antigen, hepatitis B core antibodies, but positive for HCV by 
HCV antibodies and PCR). Biochemical tests for ALT and 
ALP determination were performed following procedures 
used by Muhammad et al. (2013).  
A solid phase enzyme linked immunosorbent assay 
(ELISA), (according to Wachter et al. 1992, kits provided by 
IBL International GMBH) based on key assumption of a 
competitive ELISA was used for the in-vitro-diagnostic 
quantitative evaluation of neopterin level in human serum. 
The data obtained was evaluated statistically using 
SPSS version 16 and differences were assumed significant 
if the P-value was less than 0.05 (P < 0.05). An 
independent t-test, paired t-test and Spearman’s rho 
correlation was used to correlate different variables. 
 
RESULTS AND DISCUSSION 
Our results showed that mean serum value for both 
AST and ALT in HCV positive group was non-significantly 
higher than those of the control group with mean serum 
value of (30.54 ± 9.9IU/L) and (27.54 ±9.9 IU/L) respectively 
at P > 0.05. The results showed significantly higher (P < 
0.05) age of HCV positive group than the control group 
(Table 1). Rukiye and Fikriye (2016) have demonstrated 
higher levels of AST and ALT in HCV patients than healthy 
patients that support our findings. In a previous study mean 
values of serum ALT levels (82.7 ± 20.6 IU/L) and AST (79.2 
± 21.7 IU/L) were determined in HCV persistent group, while 
in control group mean values of serum ALT were 33.6 ± 
10.7 IU/L and AST 32.6 ± 11.4 IU/L (Tabll et al., 2011). 
Significantly higher (P < 0.001) serum concentrations of 
AST and ALT were found in HCV-monoinfected subjects 
than in those who experienced spontaneous recovery from 
HCV. Similarly, higher serum AST ((P < 0.001)) and ALT ((P 
= 0.060)) concentrations were found in HIV-positive 
compared to HIV-negative HCV patients (Huang et al., 
2016). 
 
 
 
 
 
 
Table 1. Comparison between age and laboratory data 
of healthy control group and HCV positive group. 
Parameters Healthy 
control 
( gpI) 
N=44 
HCV 
cases 
(gp II) 
N=44 
t- 
value 
P- 
value 
Age: 
Mean±S.D 
28.92±7.64 34.27±6.03 3.52 0.001 
ALT(IU/L) 
Mean±S.D 
25.04±7.76 27.54±9.9 1.394 0.167 
AST(IU/L) 
Mean±S.D 
28.09±7.92 30.54±9.9 1.359 0.178 
 
In this study 9.09% donors (4 of 44) from HCV positive 
group while 15.90% donors (7 of 44) from control group 
showed increased neopterin level. The mean neopterin 
concentration was higher in healthy control group 
(6.419±5.012 nmol/L) than in HCV positive group (5.78± 
3.75 nmol/L) with statistically non-significant difference 
between the groups (p -Value > 0.05) (Table 2). Higher 
serum neopterin levels have been found to be linked with 
various diseases including rejection and viral infections 
(Chin et al., 2008; Grebe et al., 2011). Our findings are 
against Zoller et al. (2015) who determined neopterin 
concentrations to be 7.8 ± 8.7 nmol/L and greater than 
normal (p < 0.05) in HCV patients.  
 
Table 2. Serum neopterin level in healthy control group 
and HCV positive group. 
Variables Healthy 
control  
group 
HCV 
positive 
group 
t- 
value 
P- 
value 
 Mean± S.D Mean±S.D   
Neopterin 
(nmol/L) 
6.419±5.012 5.78±3.75 0.682 0.497 
p - Value > 0.05 is non- significant, p - Value < 0.05 is 
significant. 
 
The correlation between age, ALT and AST in the 
healthy control group and the HCV positive group according 
to neopterin level showed non-significant difference between 
the groups, P > 0.05 (Table 3). From our study we did not 
find correlation between high neopterin concentrations and 
HCV antibody seropositive donations and no significant 
correlation between neopterin level and any studied 
variables (ALT, AST and age). Tabll et al. (2011) have 
demonstrated serum ALT and AST levels were significantly 
higher in group HCV positive patients than in control group 
(P value < 0.001). 
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Table 3. The correlation between age, ALT and AST 
between the studied groups. 
Correlation 
of 
Neopterin 
with 
    HCV cases 
 
Healthy group 
r p-value r p-value 
Age (year) 0.04 P > 0.05 -0.072 P > 0.05 
ALT (IU/L) - 0.255 P > 0.05 -0.014 P > 0.05 
AST (IU/L) - 0.255 P > 0.05 0.010 P > 0.05 
Non-Significant at p > 0.05, Significant at p < 0.05 
 
Table 4 and figure 1 showed that the receiver operating 
characteristic curve (ROC curve) showed that there is no 
significant area under the curve and neopterin is not a good 
marker to predict the infection of hepatitis C with specificity 
of 84.1%, sensitivity of  34.1%, PPV of 68.2% and NPV of 
56.1% for diagnosis of HCV. In a previous study it was 
illustrated that a cutoff value of serum neopterin > 18.68 
nmol/L (AUC=0.695) anticipated sensitivity 78.3%, 
specificity 58.4%, PPV 69.6% and NPV 82.6% (P=0.001) in 
HCV patients (Altonbary et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.  AUC (area under the curve) of Neopetrin level 
in studied groups 
Area under the curve  0.526 
Std. Error
a
  0.062 
P value  0.673 
 
Asymptotic 95% CI 
Lower 0.404 
Upper 0.648 
Best cutoff  8.27 
Sensitivity  34.1% 
Specificity  84.1% 
PPV  68.2% 
NPV  56.1% 
CI: Confidence Interval, NPV: Net Present Value, PPV: 
Positive Predictive Value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                               Fig. 1.  ROC curve for Neopetrin Level . 
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In the present study the seven samples which had 
elevated neopterin values but were not positive for any one 
of the screening tests, raised the issue of keeping the safety 
of the patients, so these seven samples should not be used 
for transfusion. 
So the present study further supports that increased 
neopterin concentrations in seronegative blood donations 
may be a marker for other unknown infections not screened 
for and transmission of these infections.  
      
CONCLUSION AND SUGGESTIONS 
In conclusion neopterin is a nonspecific marker for 
screening of HCV infection in blood donors may be a useful 
marker for monitoring of infectious disease activity during 
treatment.  
Also the neopterin assay thus detects a variety of 
potentially harmful diseases or conditions which would not 
be revealed by the usually employed battery of routine tests. 
Hence we conclude that the risk of transmitting new 
pathogens may be reduced using neopterin assay as a 
routine work in our blood banks. 
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